Shots:

• The new peptide MAM workflow for the BioAccord LC-MS system that helps to monitor critical quality attributes of protein-based drugs that can affect the safety & efficacy of innovator drugs and biosimilars
• By integrating BioAccord system on the waters_connect platform- scientists have a sensitive multiplexed method to accurately assess the attributes of protein-based drugs that enable rapid decision-making for product development- manufacturing- and release. The system also monitors product variants- degradation and impurities- and process stability
• The BioAccord system combines the ACQUITY UPLC I-Class and ACQUITY RDa mass detector featuring SmartMS enabled usability features

  Ref: Businesswire | Image: Twitter